Login / Signup

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.

Michael BöhmStefan D AnkerFelix MahfoudLucas LauderGerasimos S FilippatosJoao Pedro FerreiraStuart J PocockMartina BrueckmannIlias SaloustrosElke SchülerChristoph WannerFaiez ZannadMilton PackerJaved Butler
Published in: European heart journal (2022)
URL: https://www.clinicaltrials.gov Unique identifier: NCT03057951.
Keyphrases
  • blood pressure
  • study protocol
  • phase iii
  • clinical trial
  • hypertensive patients
  • phase ii
  • heart rate
  • randomized controlled trial
  • adipose tissue
  • insulin resistance
  • glycemic control
  • skeletal muscle